

**Supplementary Table 1 Timeline**

<b>Items</b>	<b>Case 1</b>	<b>Case 2</b>	<b>Case 3</b>	<b>Case 4</b>	<b>Case 5</b>	<b>Case 6</b>	<b>Case 7</b>
<b>Age (yr)</b>	44	41	54	42	39	37	33
<b>Gender</b>	Male	Female	Male	Male	Female	Female	Female
<b>Past disease history</b>	Hypertension, Fatty liver	Chronic hepatitis B	Hepatitis B carrier	None	None	None	None
<b>Initial symptom</b>	Right frontal mass	Left orbital swelling	Pulmonary infection	Bone pain	Superciliary arch pain, hypopsia	Chest, low back and leg pain	Low back pain
<b>MM type</b>	IgG-κ	k light chain	IgG-κ	IgG-κ	IgG-κ	k light chain	IgG-κ
<b>DS stage</b>	IA	IIIA	IIIA	IIIB	IIIA	IIIB	IIIA
<b>ISS stage</b>	I	I	II	III	I	III	II
<b>FISH test</b>	Normality	No testing	No testing	Normality	1q21+	1q21+	No testing
<b>D1 time</b>	2018.11	2018.4	2011.9	2007.12	2010.2	2011.1	2014.7
<b>Initial treatment</b>	Surgical resection, VRD and	Surgical resection and	T-CAD and lenalidomide maintenance	Surgical resection, T-CAD and	Surgical resection, radiotherapy,	T-CAD, BAD and thalidomide	Surgical resection and CAD

	lenalidomide maintenance therapy	radiotherapy	therapy	thalidomide maintenance therapy	T-CAD, BAD, maintenance B-CEVAD and thalidomide maintenance therapy		
<b>D2 time</b>	2019.5	2018.4	2013.10	2011.8	2010.2	2015.2	2019.4
<b>Treatment</b>	VRD and lenalidomide maintenance therapy	PDD and lenalidomide maintenance therapy	BAD and lenalidomide maintenance therapy	Surgical resection and T- CAD	T-CAD, BAD and thalidomide maintenance therapy	BAD, T-CAD and thalidomide maintenance therapy	R-DECP .BED and lenalidomide maintenance therapy
<b>Outcome</b>	Survival	Died	Died	Died	Died	Died	Survival
<b>PFS</b>	18 mo	13 mo	33 mo	44 mo	33 mo	36 mo	24 mo
<b>OS</b>	18 mo	25 mo	36 mo	127 mo	48 mo	60 mo	71 mo

D1,multiple myeloma;D2,orbital EMD; PD, disease progression; ISS, International Staging System; FISH, fluorescence in situ hybridization; VRD: Bortezomib,Lenalidomide and Dexamethsone; BAD regimen (Bortezomib, Doxorubicin and Dexamethsone); CAD: Ifosfamide, Epirubicin or Piraubicin and Dexamethsone; T-CAD: Thalidomide and CAD; B-CEVAD: Bortezomib, Etoposide, ifosfamide, Vindesine sulfate, Epirubicin, and Dexamethsone; BED regimen:(Bortezomib, Etoposide and Dexamethsone; CR:

complete remission; PR: partial remission.